Multaq given limited approval from NICE
pharmafile | August 25, 2010 | News story | Medical Communications, Sales and Marketing | Multaq, NICE, Sanofi-Aventis, atrial, dronedarone
NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients.
The guidance recommends using Multaq (dronedarone) only as a second line treatment in patients with additional cardiovascular factors whose non-permanent atrial fibrillation (AF) has not been controlled by first line therapy, usually involving beta blockers.
NICE states that Multaq should only be used in patients:
- Who have hypertension that requires drugs of at least two different classes
- Have diabetes mellitus
- Have had a stroke or systemic embolism
- Have a left atrial diameter of 50mm or greater
- Aged 70 years or older
- Who do not have unstable New York Association class III or IV heart failure
- And patients who have left ventricular ejection fraction less than 40%
The cost-effectiveness body was originally minded not to recommend the treatment, saying in January that it was too costly when compared to the generic alternative amiodarone.
It changed its mind in the latest series of draft guidance after being persuaded that Multaq was an advance over currently available treatments.
In particular, NICE said amiodarone and other anti-arrhythmia drugs carried with them the risk of raised mortality in patients, something not seen in Multaq’s data.
Multaq is used on patients who have experienced an irregular heartbeat, atrial fibrillation or atrial flutter within the past six months, but who may currently have a regular heart rhythm or will have medical treatment to return to a regular rhythm.
Multaq gained US approval in July 2009 and European approval in November, and is one of Sanofi’s most important new products.
This will come as a boost to the French company as it is depending on new drugs such as Multaq to sustain sales and offset generic competition.
Ben Adams
Related Content
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
